Crohn Disease
Leukoencephalopathy, Progressive Multifocal
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Natalizumab

Natalizumab

Natalizumab is an FDA-approved monoclonal antibody for treating multiple sclerosis and Crohn disease. Initially sanctioned in 2004 for multiple sclerosis treatment, its market presence faced a setback due to reported fatalities linked to progressive multifocal leukoencephalopathy. The FDA withdrew approval for natalizumab but later reinstated it in 2006, responding to advocacy from the multiple sclerosis community. When used judiciously alongside an advisory committee, this drug demonstrates efficacy in slowing symptom progression during flares and reducing relapse rates in individuals with relapsing-remitting multiple sclerosis. This activity discusses natalizumab’s indications, mechanism of action, administration methods, notable adverse effects, contraindications, monitoring protocols, and toxicity considerations. By assimilating this information, healthcare providers can navigate patient therapy toward optimal outcomes for those grappling with multiple sclerosis.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.